Finance

Beta
Lists
VIRP:EPA
Virbac SA
€341.00
-1.16%
(-4.00) 1D
Jun 3, 5:35:38 PM GMT+2  ·   EUR
All symbols
SymbolPriceChange% Change
Generating top insights for VIRP...
Open
€343.00
High
€344.50
Low
€338.00
Mkt. cap
2.84B
Avg. vol.
3.94K
Volume
3.43K
P/E ratio
18.94
52-wk high
€389.50
52-wk low
€296.00
EPS
€18.00
Shares outstanding
8.39M
No. of employees
6K
Open
€343.00
High
€344.50
Low
€338.00
Mkt. cap
2.84B
Avg. vol.
3.94K
Volume
3.43K
P/E ratio
18.94
52-wk high
€389.50
52-wk low
€296.00
EPS
€18.00
Shares outstanding
8.39M
No. of employees
6K
Analyst outlook
Analyst Ratings
Based on 1 analyst giving stock ratings to VIRP in the past 3 months
Buy
Buy
1
Hold
0
Sell
0
12 month forecast
Based on 1 Wall Street analyst offering 12 month price targets for VIRP in the last 3 months.
Highest
Current €341.00
€415.00 (+21.70%)
Average
€415.00 (+21.70%)
Lowest
€415.00 (+21.70%)
News stories
From sources across the web
Profile
Virbac is a French company dedicated to animal health located in Carros, near Nice. It was founded in 1968 by veterinarian Pierre-Richard Dick. The company is the world’s 6th largest veterinarian pharmaceutical group with a turnover of 1,465 million euros in 2025. The company is a limited company with a board Euronext Paris stock exchange - compartiment A and is part of the reference index: SBF 120, and eligible SRD, PEA and PEA-PME. Wikipedia
About Virbac SA
CEO-
Employees6.44K
Founded1968
HeadquartersCarros, Provence-Alpes-Côte d'Azur, France
SectorPharmaceutical industry
Websitecorporate.virbac.com
Last report
Apr 16, 2026
Fiscal period
Q1 2026
EPS / Est. (EUR)
- / -
Revenue / Est. (EUR)
384.00M / 393.00M
Fiscal Q1 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in EUR
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in EUR
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Revenue
369.14M
369.14M
363.20M
363.20M
Cost of goods sold
120.43M
120.43M
123.55M
123.55M
Cost of revenue
120.43M
120.43M
123.55M
123.55M
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
166.14M
166.14M
173.95M
173.95M
Operating expense
182.57M
182.57M
190.71M
190.71M
Total operating expenses
303.00M
303.00M
314.27M
314.27M
Operating income
66.14M
66.14M
48.93M
48.93M
Other non operating income
-18.00K
-18.00K
-120.00K
-120.00K
EBT including unusual items
62.00M
62.00M
46.85M
46.85M
EBT excluding unusual items
61.95M
61.95M
48.90M
48.90M
Income tax expense
20.88M
20.88M
12.74M
12.74M
Effective tax rate
33.68%
33.68%
27.19%
27.19%
Other operating expenses
1.02M
1.02M
1.93M
1.93M
Net income
41.20M
41.20M
34.24M
34.24M
Net profit margin
11.16%
11.16%
9.43%
9.43%
Earnings per share
-
-
-
-
Interest and investment income
1.12M
1.12M
1.15M
1.15M
Interest expense
-2.50M
-2.50M
-1.92M
-1.92M
Net interest expenses
-1.38M
-1.38M
-764.50K
-764.50K
Depreciation and amortization charges
14.09M
14.09M
13.77M
13.77M
EBITDA
78.33M
78.33M
60.18M
60.18M
Gain or loss from assets sale
48.00K
48.00K
505.50K
505.50K
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer